Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long Terms Follow-Up of the Randomized MetaspHER Study Comparing Intravenous Versus Subcutaneous Trastuzumab in Patients' With HER2-Positive Metastatic Breast Cancer.
Pivot X, Spano JP, Espie M, Jouannaud C, Pottier V, Moreau L, Extra JM, Lortholary A, Rivera P, Spaeth D, Mouri Z, Tariket F, Dupin J, Berthois A, Ionescu-Goga M, Ferhat A, Cottu P, Gligorov J. Pivot X, et al. Among authors: gligorov j. Clin Breast Cancer. 2023 Oct;23(7):e412-e419. doi: 10.1016/j.clbc.2023.06.007. Epub 2023 Jun 20. Clin Breast Cancer. 2023. PMID: 37423801
Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues.
Launay-Vacher V, Gligorov J, Le Tourneau C, Janus N, Spano JP, Ray-Coquard I, Oudard S, Pourrat X, Morere JF, Deray G, Beuzeboc P; Renal Insufficiency and Anticancer Medications (IRMA) Study Group. Launay-Vacher V, et al. Among authors: gligorov j. Breast Cancer Res Treat. 2010 Dec;124(3):745-53. doi: 10.1007/s10549-008-0131-1. Epub 2008 Aug 15. Breast Cancer Res Treat. 2010. PMID: 18704681
Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study.
Launay-Vacher V, Spano JP, Janus N, Gligorov J, Ray-Coquard I, Oudard S, Pourrat X, Morere JF, Beuzeboc P, Deray G; Renal Insufficiency and Anticancer Medications (IRMA) Study Group. Launay-Vacher V, et al. Among authors: gligorov j. Crit Rev Oncol Hematol. 2009 May;70(2):124-33. doi: 10.1016/j.critrevonc.2008.09.012. Epub 2008 Nov 5. Crit Rev Oncol Hematol. 2009. PMID: 18990585
Drug management of prostate cancer: prevalence and consequences of renal insufficiency.
Launay-Vacher V, Ayllon J, Janus N, Spano JP, Ray-Coquard I, Gligorov J, Pourrat X, Morere JF, Beuzeboc P, Deray G, Oudard S; Renal Insufficiency and Anticancer Medications (IRMA) Study Group. Launay-Vacher V, et al. Among authors: gligorov j. Clin Genitourin Cancer. 2009 Oct;7(3):E83-9. doi: 10.3816/CGC.2009.n.029. Clin Genitourin Cancer. 2009. PMID: 19815487
Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Curtit E, Nouyrigat P, Dohollou N, Levy E, Lortholary A, Gligorov J, Facchini T, Jaubert D, Maille N, Pivot X, Grangé V, Cals L. Curtit E, et al. Among authors: gligorov j. Eur J Cancer. 2011 Nov;47(16):2396-402. doi: 10.1016/j.ejca.2011.08.004. Epub 2011 Sep 13. Eur J Cancer. 2011. PMID: 21920729 Clinical Trial.
[Renal insufficiency and breast cancer].
Beuzeboc P, Le Tourneau C, Gligorov J, Janus N, Spano JP, Ray-Coquard I, Deray G, Launay-Vacher V. Beuzeboc P, et al. Among authors: gligorov j. Bull Cancer. 2012 Mar 1;99(3):309-15. doi: 10.1684/bdc.2011.1478. Bull Cancer. 2012. PMID: 22106161 Free article. French.
Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients.
Lévy P, Gligorov J, Antoine M, Rezai K, Lévy E, Selle F, Saintigny P, Lokiec F, Avenin D, Beerblock K, Lotz JP, Bernaudin JF, Fajac A. Lévy P, et al. Among authors: gligorov j. Breast Cancer Res Treat. 2013 Jun;139(2):421-8. doi: 10.1007/s10549-013-2545-7. Epub 2013 May 11. Breast Cancer Res Treat. 2013. PMID: 23666532
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.
Pivot X, Gligorov J, Müller V, Barrett-Lee P, Verma S, Knoop A, Curigliano G, Semiglazov V, López-Vivanco G, Jenkins V, Scotto N, Osborne S, Fallowfield L; PrefHer Study Group. Pivot X, et al. Among authors: gligorov j. Lancet Oncol. 2013 Sep;14(10):962-70. doi: 10.1016/S1470-2045(13)70383-8. Epub 2013 Aug 19. Lancet Oncol. 2013. PMID: 23965225 Clinical Trial.
240 results